Novartis AG (NVSEF)
163.60
+5.99
(+3.80%)
USD |
OTCM |
Aug 24, 16:00
Novartis Net Income (Quarterly) : 3.257B for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.257B |
| March 31, 2026 | 3.156B |
| December 31, 2025 | 2.404B |
| September 30, 2025 | 3.93B |
| June 30, 2025 | 4.024B |
| March 31, 2025 | 3.609B |
| December 31, 2024 | 2.82B |
| September 30, 2024 | 3.185B |
| June 30, 2024 | 3.246B |
| March 31, 2024 | 2.688B |
| December 31, 2023 | 2.638B |
| September 30, 2023 | 1.513B |
| June 30, 2023 | 2.271B |
| March 31, 2023 | 2.15B |
| December 31, 2022 | 1.315B |
| September 30, 2022 | 1.33B |
| June 30, 2022 | 1.695B |
| March 31, 2022 | 2.219B |
| December 31, 2021 | 16.31B |
| September 30, 2021 | 2.758B |
| June 30, 2021 | 2.895B |
| March 31, 2021 | 2.059B |
| December 31, 2020 | 2.099B |
| September 30, 2020 | 1.932B |
| June 30, 2020 | 1.867B |
| Date | Value |
|---|---|
| March 31, 2020 | 2.173B |
| December 31, 2019 | 1.129B |
| September 30, 2019 | 2.041B |
| June 30, 2019 | 2.109B |
| March 31, 2019 | 1.868B |
| December 31, 2018 | 1.22B |
| September 30, 2018 | 1.882B |
| June 30, 2018 | 7.728B |
| March 31, 2018 | 1.97B |
| December 31, 2017 | 1.976B |
| September 30, 2017 | 2.083B |
| June 30, 2017 | 1.979B |
| March 31, 2017 | 1.665B |
| December 31, 2016 | 936.00M |
| September 30, 2016 | 1.945B |
| June 30, 2016 | 1.806B |
| March 31, 2016 | 2.011B |
| December 31, 2015 | 1.054B |
| September 30, 2015 | 1.812B |
| June 30, 2015 | 1.856B |
| March 31, 2015 | 2.306B |
| December 31, 2014 | 2.448B |
| September 30, 2014 | 3.102B |
| June 30, 2014 | 2.723B |
| March 31, 2014 | 2.968B |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Roche Holding AG | -- |
| Addex Therapeutics Ltd. | -2.184M |
| Oculis Holding AG | -12.61M |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 14.41B |
| Total Expenses (Quarterly) | 11.14B |
| EPS Diluted (Quarterly) | 1.705 |
| Enterprise Value | 341.21B |
| Gross Profit Margin (Quarterly) | 74.47% |
| Profit Margin (Quarterly) | 22.61% |
| Earnings Yield | 4.05% |
| Operating Earnings Yield | 5.14% |
| Normalized Earnings Yield | 4.347 |